Sodium-glucose cotransporter inhibitors reduce cardiovascular outcomes regardless eGFR range in patients with heart failure. Systematic review and meta-regression meta-analysis

Back

ESC Professional Premium Access

Sodium-glucose cotransporter inhibitors reduce cardiovascular outcomes regardless eGFR range in patients with heart failure. Systematic review and meta-regression meta-analysis

Session: More insights into SGLT2i in heart failure

Topic: Pharmacotherapy

Speaker: Doctor I. Cunha (Sao Paulo, BR)

Event: ESC Congress 2023

Congress Presentation

Add to my library

About the speaker

Doctor Ivna Cunha

Instituto do Coracao FMUSP, Sao Paulo (Brazil)

0 follower

5 more presentations in this session

The effect of sglt-2 inhibitor dapagliflozin on adropin serum levels in patients with chronic heart failure and concomitant type 2 diabetes mellitus

Speaker: Professor A. Berezin (Salzburg, AT)

Uptake of SGLT2i therapy among patients hospitalized with heart failure: Insights from the veterans affairs healthcare system

Speaker: Doctor A. Varshney (Palo Alto, US)

Efficacy of dapagliflozin according to geographic regions in patients with heart failure: a patient-level pooled analysis of DAPA-HF and DELIVER

Speaker: Doctor T. Kondo (Glasgow, GB)

Effect of sodium-related glucose transporter 2 -Inhibitors on exercise capacity in heart failure patients with reduced ejection fraction, does etiology matter?

Speaker: Doctor E. Coppo (Jerez de la Frontera, ES)

Prognostic implications of angiopoietin-2 in heart failure and the influence of empagliflozin: the EMPEROR program

Speaker: Professor J. Butler (Dallas, US)

Access the full session

More insights into SGLT2i in heart failure

Speakers: Doctor I. Cunha, Professor A. Berezin, Doctor A. Varshney, Doctor T. Kondo, Doctor E. Coppo...

Access

About the event

ESC Congress 2023

25 August - 28 August 2023

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources